Compare NSRX & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSRX | GNTA |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | Israel | Italy |
| Employees | N/A | 9 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 33.8M |
| IPO Year | 2024 | 2021 |
| Metric | NSRX | GNTA |
|---|---|---|
| Price | $3.57 | $0.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $19.67 | N/A |
| AVG Volume (30 Days) | 8.3K | ★ 46.3K |
| Earning Date | 03-25-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.98 | $0.55 |
| 52 Week High | $9.50 | $10.00 |
| Indicator | NSRX | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
Genenta Science SPA is an industrial consolidator focused on acquiring majority or full ownership of privately held, established companies operating in Italian national-security-regulated sectors. Its acquisition activities span aerospace, defense, national security (including cybersecurity), and biotechnology/biosecurity, with a focus on businesses covered by Italy's Golden Power legislation.